Equities researchers at SVB Leerink initiated coverage on shares of Tango Therapeutics (NASDAQ:TNGX) in a research note issued on Monday, September 20th, Analyst Price Targets reports. The brokerage set an “outperform” rating on the stock. SVB Leerink also issued estimates for Tango Therapeutics’ Q3 2021 earnings at ($0.25) EPS, Q4 2021 earnings at ($0.30) EPS, FY2021 earnings at ($1.27) EPS, FY2022 earnings at ($1.21) EPS, FY2023 earnings at ($1.55) EPS, FY2024 earnings at ($1.89) EPS and FY2025 earnings at ($2.17) EPS.
A number of other research firms have also weighed in on TNGX. Guggenheim initiated coverage on shares of Tango Therapeutics in a research report on Tuesday, September 7th. They set a “buy” rating and a $16.00 target price for the company. Wedbush began coverage on Tango Therapeutics in a research report on Tuesday, September 7th. They set an “outperform” rating for the company. Finally, The Goldman Sachs Group initiated coverage on Tango Therapeutics in a report on Tuesday, September 7th. They issued a “buy” rating and a $17.00 target price on the stock.
Shares of NASDAQ TNGX traded down $0.30 during trading hours on Monday, hitting $13.26. 196,337 shares of the stock were exchanged, compared to its average volume of 83,304. Tango Therapeutics has a one year low of $8.90 and a one year high of $18.84.
Tango Therapeutics Inc is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc, formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.
Further Reading: Day Trading
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.